"On the weekend in which psychonauts celebrate Bicycle Day, Donald Trump was in the Oval Office double-checking that he was correctly pronouncing the name of a lesser-known psychedelic, ibogaine, as he signed a landmark executive order to accelerate research into hallucinogens, and to increase access."
"Thanks to the order, the US Food and Drug Administration (FDA) will as early as this week fast-track the reviews of three incoming psychedelic drug candidate applications that have already received breakthrough therapy designations."
"The order states that investigational psychedelic drugs more broadly, including ibogaine, which early studies suggest significantly improves symptoms of traumatic brain injury while providing relief from opioid withdrawal symptoms, will become available under right to try legislation."
Donald Trump signed an executive order to expedite research into psychedelics, including ibogaine, psilocybin, and MDMA. This order allows the FDA to fast-track reviews of psychedelic drug applications. The move indicates a significant policy shift within the Trump administration regarding psychedelics, with potential implications for the multibillion-dollar market. The order also allows investigational psychedelic drugs to be available under right to try legislation for terminally ill patients. This development may lead to conflicts with the Drug Enforcement Administration over psychedelic reform.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]